6:30 AM SIGN-IN & BREAKFAST • 7:00 AM - 8:30 AM
BANDOL 1 (NEW WYNN SPACE)
CE: A Review of Psoriatic Arthritis Therapies for Specialty Pharmacists and Payers
Psoriatic arthritis is an inflammatory form of arthritis, affecting approximately 30% of patients with psoriasis. Up to 60% of patients with psoriatic arthritis experience progressive, erosive, and deforming joint damage. Early intervention is critical to improving clinical outcomes in psoriatic arthritis. The introduction of biologic agents, usually in combination with oral small molecules, have changed the treatment landscape. Despite advances in therapy, some patients do not respond to oral small molecules or anti-TNF-α. Newer classes of biologics have emerged, targeting interleukin (IL)-17, IL-23/23, and JAK molecules to address this unmet need. This live program features a clinical expert in psoriatic arthritis and a specialty pharmacist to review the pathophysiology and burden of psoriatic arthritis, examine clinical data for current and emerging therapies, investigate the costs associated with psoriatic arthritis, and explore how specialty pharmacists can better help patients with psoriatic arthritis.